Business
Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study finds – CNBC
- Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study findsCNBC
- Eisai, Biogen support long-term use of Alzheimer’s drug Leqembi with new dataSTAT
- Expanding the Knowledge Profile and Treatment Capabilities of Lecanemab: Lynn Kramer, MD, FAANNeurology Live
- Japanese company Eisai plans to use blood test to assess Alzheimer’s drug suitabilityNikkei Asia
- Long-term treatment data for lecanemab to be presented at AAIC 2024StockTitan
